Today's Trend
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares appear to be getting support from a strong first-quarter update, even as analysts trimmed some near-term earnings estimates. The stock is likely reacting to a mix of better-than-expected quarterly results, robust XDEMVY sales growth, and upbeat long-term outlook commentary.
- Tarsus reported Q1 EPS of -$0.16, beating expectations for a -$0.40 loss, and revenue of $162.05 million, above the $149.60 million consensus. Article Title
- The company said Q1 XDEMVY net product sales topped $145 million, up more than 85% year over year, and reaffirmed 2026 guidance of $670 million to $700 million in XDEMVY sales. Article Title
- Management also highlighted broader business momentum, including stronger prescribing trends and the start of a Phase 2 Lyme disease prevention trial for TP-05. Article Title
- LifeSci Capital and HC Wainwright mostly kept bullish ratings on Tarsus, but several firms slightly lowered near-term EPS estimates after the report, which could temper enthusiasm. Article Title
- Lifescis Capital cut Q1, Q2, Q3 and FY2026 EPS estimates, and HC Wainwright trimmed FY2027-FY2029 estimates slightly, reflecting continued losses in the near term despite long-term optimism. Article Title
Overall, Tarsus Pharmaceuticals (NASDAQ:TARS) looks to be moving on the combination of a strong quarterly beat and accelerating product sales, with the stock also facing some pressure from trimmed short-term earnings forecasts.